Mediera Corporation (TPEX:5398)
Taiwan · Delayed Price · Currency is TWD 22.40
-0.60 (-2.61%)
Jan 22, 2026, 1:30 PM CST
Mediera Revenue
Mediera had revenue of 72.02M TWD in the quarter ending September 30, 2025, with 5.48% growth. This brings the company's revenue in the last twelve months to 240.30M, up 15.31% year-over-year. In the year 2024, Mediera had annual revenue of 238.48M with 23.63% growth.
Revenue (ttm)
240.30M
Revenue Growth
+15.31%
P/S Ratio
4.73
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238.48M | 45.59M | 23.63% |
| Dec 31, 2023 | 192.90M | -64.65M | -25.10% |
| Dec 31, 2022 | 257.55M | -94.01M | -26.74% |
| Dec 31, 2021 | 351.56M | -16.33M | -4.44% |
| Dec 31, 2020 | 367.88M | -65.09M | -15.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anxo Pharmaceutical | 883.22M |
| Excelsior Biopharma | 859.77M |
| Prince Pharmaceutical | 798.27M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| GeneFerm Biotechnology | 654.88M |
| Tien Liang BioTech | 467.02M |
| General Biologicals | 251.38M |